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‘‘Probably no other disease in human
history has been associated with social and
political activism to the extent that the
HIV epidemic has,’’ says the AIDS Activism
Web site [1]. Such activism played a huge
role in reducing the costs of antiretroviral
drugs in developing countries [2]. Five
years ago, one of us (GY) argued that
similar activism was needed to raise
awareness of shortfalls in global efforts to
control malaria [3]. We believe there are
now signs of an evolving ‘‘malaria activ-
ism,’’ which has resulted in two major
successes.
The first wave of malaria activism
highlighted the disparity between the
massive burden of disease and the tiny
amount of international development as-
sistance dedicated to its control [4,5]. This
assistance amounted to just US$100 mil-
lion in 2000, yet the World Health
Organization (WHO) Commission on
Macroeconomics and Health estimated
that global malaria control would cost
US$1.5–US$2.5 billion annually world-
wide [5]. Advocacy by researchers, non-
governmental organizations, journalists,
and editors helped motivate donors to
increase their malaria commitments [5–7].
By 2007, according to a study by Bob
Snow (KEMRI-Wellcome Trust, Kenya)
and colleagues, international financing of
malaria control had increased to around
US$1 billion (40% came from the Global
Fund to Fight AIDS, Tuberculosis, and
Malaria) [7]. Although this upward trend
in funding was a victory for ‘‘malaria
activists,’’ there is still no room for
complacency, since the study found insuf-
ficient funding to fully scale up malaria
control worldwide. Commenting on the
study, Anthony Kiszewski (Bentley Uni-
versity, USA) argued that while under-
funding continues, the fashionable talk of
eliminating malaria seems ‘‘quixotic at
best’’ [8].
The second wave of malaria activism
focused on exposing an inconvenient
truth. A substantial proportion of the
additional malaria funds was being spent
on monotherapies (chloroquine, sulfadox-
ine-pyrimethamine), often ineffective in
Africa because of parasite resistance
[9,10], rather than more efficacious arte-
misinin-based combination therapy
(ACT). Activism by academics, journalists,
and newspaper editors scored a further
success: in 2004 the Global Fund repro-
grammed its financing to spend more on
ACT, while the United Nations (UN)
health agencies pledged to discontinue
support for the use of ineffective mono-
therapies [11,12]. Since then, ACT has
been scaled up across Africa [13].
These are big victories. But one bench-
mark of successful ACT scale-up is
whether the drugs are available at the
point of care [14]. One of us (GY) has just
returned from a health reporting fellow-
ship in East Africa [15], where he found
that ACT ‘‘stock-outs’’ (shortages) were
common. This observation is backed by
empirical evidence from many African
countries [14,16,17]. For example, in
2008, two years after Kenya introduced
artemether-lumefantrine (AL) as first-line
treatment for uncomplicated malaria, Beth
Kangwana (KEMRI-Wellcome Trust,
Kenya) and colleagues surveyed govern-
ment health facilities to assess AL avail-
ability [14]. The drug comes in four
different weight-specific blister packs. A
quarter of the surveyed facilities had none
of the four packs.
So it’s time for a ‘‘third wave’’ of
malaria activism to raise awareness of this
ACT stock-out crisis. Interviewed at the
KEMRI-Wellcome Trust Research Cen-
tre in Nairobi, Bob Snow, coauthor of the
Kenyan survey [14], said the current
situation is two steps forward, three steps
back. ‘‘We abandoned chloroquine when
it failed to cure one in four patients and
was available everywhere,’’ he said. ‘‘We
now have a drug that cures 100% of
patients but is not available in one in four
clinics.’’ Snow said that the stock-out crisis
results from ‘‘inadequate ordering, distri-
bution, and supply—it’s a health systems
issue.’’
Chloroquine cost pennies and was being
given presumptively to any child with
fever. Supplying ACT to the right patient
at the right time is more complex. The
drug is expensive (around US$6–10 per
treatment). Because it comes in four
weight-specific packs, countries are essen-
tially managing the supply of four drugs,
not one. And there is growing pressure for
public sector health facilities to abandon
presumptive treatment and use a rapid
diagnostic test (RDT) before prescribing
ACT [18]. So the central medical supplies
agency of each country is in effect
managing the flow of five products.
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products to be available at the point of
care in public sector health facilities,
starting with adequate funding. There
are still funding shortfalls to cover a
country’s essential stocks, including buffer
stocks. Interviewed in Nairobi, Elizabeth
Juma, who heads the Division of Malaria
Control in Kenya’s Ministry of Health,
said: ‘‘For a buffer, you need nine months
of stock at a cost of about $6m.’’ It’s
critical that Kenya gets buffer stocks, she
said. ‘‘We need to quantify and request
funds for that.’’
If a developing country has adequate
funding, which in most cases comes via the
Global Fund [19], the next step is to
procure sufficient high-quality drug. Ini-
tially, there was only one fixed-dose ACT
(AL) and countries usually obtained it via
the WHO at cost price for public sector
use (as set by a formal agreement with the
manufacturer). As new suppliers and new
types of ACT became available (WHO
prequalified ACTs are listed at [20]),
countries used a wider range of procure-
ment procedures. Of these, national pro-
curement by open tendering has been
increasingly encouraged by international
funding agencies because it fosters country
ownership of the process, and the compe-
tition between ACT suppliers can bring
down drug prices. But the process can face
administrative and bureaucratic delays
and hurdles, particularly in countries with
under-resourced health and regulatory
systems [14]. Drug companies have some-
times attempted to sway the tendering
process in their favor, such as by spreading
misinformation about their competitors,
which has resulted in significant delays in
procurement (Andrea Bosman, personal
communication).
After procurement, the drug must be
distributed from central medical stores to
peripheral health facilities. In countries
with weak health information systems,
stock-outs can occur because stock flows
aren’t being adequately tracked. There
may be no data on how many patients are
being treated or which facilities are
running low on ACT. Difficulty in pre-
dicting ACT requirements centrally and
peripherally can lead to an underestima-
tion of need. ‘‘The whole science of
commodities prediction is underdevel-
oped,’’ said Snow.
To add further complexity, the cost of
ACT purchased in the private sector is set
to fall to US$0.2–0.5 per treatment, thanks
to a global subsidy, the Affordable Med-
icines Facility–malaria (AMFm) [21]. In a
pilot study in Tanzania, introducing
subsidized ACT was associated with a
rapid increase in the proportion of people
accessing the drug from private shops [22].
While this study suggests that the AMFm
can improve private sector access to ACT,
Suerie Moon and colleagues warn that the
subsidy could undermine public-sector
ACT provision (for example, in the event
of ACT shortages, the AMFm would be
competing for limited ACT stock) [23].
The AMFm also introduces a confusing
double standard into malaria manage-
ment. On the one hand, there’s a push
for the public sector to use RDTs and
educate people that fevers aren’t always due
to malaria. On the other, the AMFm
offers ACT over the counter, sold by
private providers who have an incentive to
maximize sales and no training or facilities
to use RDTs. The implicit message in the
private sector: your child with fever has
malaria and needs presumptive over-the-
counter ACT.
What might the ‘‘third wave’’ of malaria
activism look like? Publicizing ACT stock-
outs is a crucial element. Two examples
are Sarah Boseley’s news feature on stock-
outs in Uganda [24] and the launch of
Africa’s Stop Stock-outs campaign [25].
Advocacy must also focus on ensuring that
the ACT supply chain is made less
vulnerable. Donors must step up to fill
the funding gaps identified by Snow and
colleagues [7]. Endemic countries need
technical assistance from the WHO and
the Global Fund to build national capacity
for ACT procurement, and to develop
stock management information systems.
Pilot projects are needed to test the
efficacy of these information systems (Roll
Back Malaria, for example, is piloting the
‘‘SMS for Life’’ project, which uses text
messages to track ACT stocks [26]). The
impact of the AMFm on public sector
provision of ACT needs to be monitored.
And there needs to be a major investment
into research on forecasting ACT require-
ments internationally, nationally, and in
peripheral clinics and on managing com-
modities. Such research doesn’t sound as
exciting as, say, developing a new malaria
vaccine or medicine, but it is crucially
important in preventing stock-outs and
thus malaria deaths—malaria activism’s
ultimate goal.
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